BILLERICA, Mass.--(BUSINESS WIRE)--In response to the FDA News Release “FDA Allows Marketing of Four ‘Next Generation’ Gene Sequencing Devices,” RainDance Technologies issued the following statement today:
“The first FDA clearance of a Next-Generation DNA Sequencing System is a significant milestone for the genomics industry and a strong validation of the recent advances in technology performance and data analysis. Sequencing-based testing is the future of healthcare, and RainDance is committed to advancing this technology further by providing tools that enable our customers to target specific, actionable regions of the genome, more cost-effectively, accurately and at higher-throughput using any next-generation sequencer.”
About RainDance Technologies
RainDance Technologies is focused on better healthcare outcomes and lowering costs for the research, detection and treatment of cancers and inherited diseases. The company’s innovative RainStorm™ digital droplet technology powers next-generation sequencing and genetic testing systems that deliver dramatically superior performance, cost, interpretability, and ease of use. RainDance systems are used routinely in major academic research institutions, clinical genetics laboratories, and hospitals around the world. Based in Billerica, Massachusetts, the company supports customers through its international sales and service operations as well as a global network of distributors and commercial service providers. For more information, please visit www.RainDanceTech.com.
The RainDrop Digital PCR System is for Research Use Only; not for use in diagnostic procedures.
RainDance Technologies, the RainDance Technologies logo, RainDrop, and RainStorm are trademarks of RainDance Technologies, Inc. All other brands may be trademarks of their respective holders.
